☆ 4.4 Article

Primary pulmonary lymphoepithelioma-like carcinoma treated with immunotherapy: A case report and literature review

THORACIC CANCER (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015

Andrew G. Nicholson et al.

Summary: The 2021 WHO Classification of Thoracic Tumours focuses on the application of genetics and molecular pathology, providing specific classifications and diagnostic criteria for various tumors, while emphasizing new tumor features and concepts.

JOURNAL OF THORACIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma

Zuohong Wu et al.

Summary: The study found that immune checkpoint inhibitors may be a promising treatment for advanced PPLELC patients, with most patients showing a positive response to this treatment, and further large clinical trials are needed to support this finding.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Molecular characteristics of primary pulmonary lymphoepithelioma-like carcinoma based on integrated genomic analyses

Bojiang Chen et al.

Summary: This study explored the genomic features of pLELC and compared them with other types of lung cancer. It was found that pLELC patients had better survival rates and high PD-L1 or p53 expression was associated with extended disease-free survival. pLELC had 14 frequently mutated genes and two miR-BARTs were discovered to potentially be involved in tumorigenesis.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Article Pathology

A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung

Zhanhong Xie et al.

MODERN PATHOLOGY (2020)

Add to Collection

Article Oncology

First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma

Zuan Lin et al.

LUNG CANCER (2019)

Add to Collection

Article Oncology

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

Ranee Mehra et al.

BRITISH JOURNAL OF CANCER (2018)

Add to Collection

Article Pathology

Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma

Anthony W. H. Chan et al.

MODERN PATHOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Paul T. Nghiem et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Martin Reck et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Oncology

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer

Joseph McLaughlin et al.

JAMA ONCOLOGY (2016)

Add to Collection

Review Oncology

Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature

Chul Kim et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2016)

Add to Collection

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

H. Borghaei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.